A Phase 2 interventional study of AeroFact and nCPAP in Respiratory Distress Syndrome in Premature Infant, sponsored by Aerogen Pharma Limited. Completed at 41 sites in 2 countries. Open to participants aged 26 Weeks to 31 Weeks. Per ClinicalTrials.gov, last updated 2025-08-07.
Sponsored by Aerogen Pharma Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 324 studies in Respiratory Distress Syndrome with a site in United States — 46 open to participants now, 56 under way, 7 of them phase 3. Respiratory Distress Syndrome · United States.
Among the 324 studies in Respiratory Distress Syndrome with a site in United States, this one is the 45th largest by enrollment of the 250 interventional ones that give a count, is one of 63 that started in 2020, is one of 74 in phase 2, and was the 174th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →46 of the 324 studies in Respiratory Distress Syndrome with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 7 days–30 days
Ohio State University · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 0 hrs–72 hrs
Massachusetts General Hospital · Sites in United States
Ages 18–80
Implicit Bioscience · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 26 Weeks to 31 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
324 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 101 · Phase 3 46 · Phase 4 6
First in 1991; this study’s year is marked. 63 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 261 is above the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 52 across the 250 interventional studies, 85 across the 68 observational. Of the 220 that completed or were terminated, 101 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 324 have an industry lead sponsor. The 10 most frequent:
Aerogen Pharma Limited is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Aerogen Pharma Limited has 2 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
20 of the studies in Respiratory Distress Syndrome with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06776783Phase 3Aerogen Pharma LimitedSafety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome | 2027-05 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05354141Phase 3Direct Biologics, LLCExtracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS) | 2027-11-30 |
| NCT04369599Emory UniversityTrans Thoracic Manipulation of Ventilation/Perfusion: the V/Q System | 2026-11 |
| NCT07674953University of ArkansasHow Different Levels of CPAP Affect Oxygen Delivery and Lung Expansion in Preterm Infants | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 324 studies in Respiratory Distress Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.
Part I Primary Objective To determine an optimal dose of AeroFact administered by nasal continuous positive airway pressure (nCPAP) versus stand of care in reducing the rate of intubation/cannulation and bolus surfactant instillation in the first 7 days after birth.
Part II Primary Objective To evaluate pulmonary outcomes and respiratory utilization at 3, 6, 9, and 12 months post-menstrual age (PMA)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Standard of Care (nasal continuous positive airway pressure-nCPAP) with instilled bolus surfactant when medically necessary
Other: nCPAP
AeroFact-low dose SF-RI 1
Drug: AeroFact
AeroFact-high dose SF-RI 1
Drug: AeroFact
Aerosolized SF-RI 1
Also known as: SF-RI 1
nCPAP (nasal continuous positive airway pressure) alone
Intubation/Cannulation and Instilled Surfactant
Number of patients who require intubation/cannulation with bolus surfactant instillation
Time frame: First 7 days of life
Time to First Intubation/Cannulation and Bolus Surfactant Instillation
Time from randomization to intubation/cannulation and bolus surfactant instillation in the first 7 days of life
Time frame: First 7 days of life
Proportion of Infants Who Received Multiple Doses of Bolus Surfactant
Time frame: First 7 days of life
Number of Days on Invasive Mechanical Ventilation
Total number of days each participant required support with invasive mechanical ventilation
Time frame: Assessed daily from birth to 40 weeks post-menstrual age or discharge
Proportion of Patients Survived Without Bronchopulmonary Dysplasia (BPD) at 36 Weeks Post-menstrual Age (PMA)
Total number of patients per treatment group who were alive and did not experience BPD at 36 weeks PMA
Time frame: Birth to 36 weeks post-menstrual age
Proportion of Patients Survived Without Bronchopulmonary Dysplasia (BPD) at 40 Weeks Post-menstrual Age (PMA)
Total number of patients per treatment group who were alive and did not experience BPD at 40 weeks PMA
Time frame: Birth to 40 weeks post-menstrual age
| Milestone | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact |
|---|---|---|---|
| Started | 92 | 83 | 86 |
| Completed | 89 | 80 | 81 |
| Not completed | 3 | 3 | 5 |
| Withdrew: Withdrawal by subject | 1 | 0 | 3 |
| Withdrew: Death | 2 | 3 | 2 |
| Milestone | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact |
|---|---|---|---|
| Started | 89 | 80 | 81 |
| Completed | 74 | 71 | 71 |
| Not completed | 15 | 9 | 10 |
| Withdrew: Lost to follow-up | 12 | 8 | 9 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 1 | 0 |
Number of patients who require intubation/cannulation with bolus surfactant instillation
| Participants | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact |
|---|---|---|---|
| Intubation/Cannulation and Instilled Surfactant | 45 | 21 | 26 |
Time from randomization to intubation/cannulation and bolus surfactant instillation in the first 7 days of life
| hours | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact |
|---|---|---|---|
| Time to First Intubation/Cannulation and Bolus Surfactant Instillation | 17.5 (2.0 to 53.9) | 13.6 (3.2 to 43.4) | 22.4 (1.8 to 53.7) |
| Participants | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact |
|---|---|---|---|
| Proportion of Infants Who Received Multiple Doses of Bolus Surfactant | 7 | 1 | 5 |
Total number of days each participant required support with invasive mechanical ventilation
| Days | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact |
|---|---|---|---|
| Number of Days on Invasive Mechanical Ventilation | 4.8 ± 7.1 | 6.0 ± 16.7 | 4.0 ± 4.7 |
Total number of patients per treatment group who were alive and did not experience BPD at 36 weeks PMA
| Participants | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact |
|---|---|---|---|
| Proportion of Patients Survived Without Bronchopulmonary Dysplasia (BPD) at 36 Weeks Post-menstrual Age (PMA) | 69 | 55 | 53 |
Total number of patients per treatment group who were alive and did not experience BPD at 40 weeks PMA
| Participants | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact |
|---|---|---|---|
| Proportion of Patients Survived Without Bronchopulmonary Dysplasia (BPD) at 40 Weeks Post-menstrual Age (PMA) | 74 | 58 | 56 |
Collected over AEs and SAEs were collected from randomization through NICU discharge or 40 weeks post-menstrual age (PMA) in Part 1. Only fatal SAEs were collected for up to 12 months in Part 2.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control: nCPAP Alone | 2/92 (2.2%) | 7/92 (7.6%) | 43/92 (46.7%) |
| Drug: Low Dose AeroFact | 3/83 (3.6%) | 9/83 (10.8%) | 45/83 (54.2%) |
| Drug: High Dose AeroFact | 2/86 (2.3%) | 5/86 (5.8%) | 42/86 (48.8%) |
| Event | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact |
|---|---|---|---|
| Necrotizing enterocolitis neonatalGastrointestinal disorders | 2/92 | 2/83 | 2/86 |
| Gastrointestinal perforationGastrointestinal disorders | 1/92 | 2/83 | 0/86 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/92 | 2/83 | 2/86 |
| Pulmonary hemorrhage neonatalRespiratory, thoracic and mediastinal disorders | 0/92 | 2/83 | 0/86 |
| Intraventricular hemorrhage neonatalNervous system disorders | 0/92 | 2/83 | 0/86 |
| Cardiac dysfunctionCardiac disorders | 0/92 | 1/83 | 0/86 |
| Acute kidney injuryRenal and urinary disorders | 0/92 | 1/83 | 0/86 |
| SepsisInfections and infestations | 1/92 | 0/83 | 1/86 |
| Meconium ileusGastrointestinal disorders | 1/92 | 0/83 | 0/86 |
| Cardiac tamponadeCardiac disorders | 1/92 | 0/83 | 0/86 |
| Event | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact |
|---|---|---|---|
| Intraventricular hemorrhage neonatalNervous system disorders | 6/92 | 15/83 | 18/86 |
| Retinopathy or prematurityEye disorders | 14/92 | 13/83 | 13/86 |
| Patent ductus arteriosusCongenital, familial and genetic disorders | 11/92 | 5/83 | 4/86 |
| Bradycardia neonatalCardiac disorders | 2/92 | 6/83 | 1/86 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 3/92 | 5/83 | 4/86 |
| Necrotizing enterocolitis neonatalGastrointestinal disorders | 5/92 | 5/83 | 5/86 |
| SepsisInfections and infestations | 4/92 | 5/83 | 3/86 |
| Patent ductus arteriosus repairSurgical and medical procedures | 4/92 | 1/83 | 0/86 |
| Gastrointestinal perforationGastrointestinal disorders | 1/92 | 3/83 | 0/86 |
| Infantile apneaRespiratory, thoracic and mediastinal disorders | 3/92 | 1/83 | 1/86 |
All randomized patients were included in the ITT and Safety analysis populations, regardless of whether or not they received study treatment.
| Age, Continuous(weeks gestational age) | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact | Total |
|---|---|---|---|---|
| Mean | 29.2 ± 1.3 | 29.1 ± 1.4 | 29.1 ± 1.5 | 29.2 ± 1.4 |
| Sex: Female, Male(Participants) | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact | Total |
|---|---|---|---|---|
| Female | 47 | 38 | 37 | 122 |
| Male | 45 | 45 | 49 | 139 |
| Ethnicity (NIH/OMB)(Participants) | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact | Total |
|---|---|---|---|---|
| Hispanic or Latino | 13 | 22 | 12 | 47 |
| Not Hispanic or Latino | 77 | 58 | 72 | 207 |
| Unknown or Not Reported | 2 | 3 | 2 | 7 |
| Race (NIH/OMB)(Participants) | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 3 | 1 | 6 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 16 | 12 | 15 | 43 |
| White | 57 | 50 | 48 | 155 |
| More than one race | 0 | 0 | 2 | 2 |
| Unknown or Not Reported | 16 | 20 | 14 | 50 |
| Birth weight(grams) | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact | Total |
|---|---|---|---|---|
| Mean | 1195.1 ± 297.9 | 1245.1 ± 301.5 | 1248.7 ± 303.9 | 1228.7 ± 300.9 |
| Vaginal delivery(Participants) | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact | Total |
|---|---|---|---|---|
| Count of participants | 14 | 25 | 19 | 58 |
| Multiple gestation(Participants) | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact | Total |
|---|---|---|---|---|
| Count of participants | 30 | 29 | 26 | 85 |
| Age at Randomization(hours) | Control: nCPAP Alone | Drug: Low Dose AeroFact | Drug: High Dose AeroFact | Total |
|---|---|---|---|---|
| Mean | 10.0 ± 7.2 | 8.2 ± 6.5 | 8.9 ± 6.9 | 9.1 ± 6.9 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2020 to primary completion in Aug 2023, 41 months.
Results were first posted in Aug 2025, 2 years after primary completion.
Of 59 phase 2 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 41 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
Aerogen Pharma Limited